ARIAD Pharmaceuticals IncNASDAQ:ARIA

Help
Symbol Lookup
    No Matches were found for
    Additional matches for ...
     
    Go
    OverviewChartsNewsFundamentalsEarningsReportsCalendarOptionsTechnical Insight

    Symbol Lookup

    Close

    Search Criteria

    Name or Symbol

    Security Type

    Fund Categories

    Market

    Expiration Filter

    Chain Type

    Submit
    Wednesday June 19, 2013 8:31 AM ET. Data delayed 15 minutes.
    17.78
    0.00 (0.00%)
    Price HistoryRefresh
    Bid/Lots
    17.51/5
    Ask/Lots
    18.24/5
    Open/Prev Close
    0.00/17.78
    Day Range
    -----
    52-Week Range
    15.35-25.40
    Vol/Avg Daily Vol
    0.0/2.3M

    ARIA Article

    Go

    Yesterday

    ARIAD Honored with Gold Stevie(R) Awards as Pharmaceutical Company of the Year at 2013 American Business Awards
    15 hours ago by Business Wire
    Companies Mentioned: ARBU, ARIA

    ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it was honored with two Gold Stevie(R) Awards in the categories of Company of the Year, Pharmaceuticals and Executive of the Year, Pharmaceuticals. Harv...

    ARIAD Honored with Gold Stevie(R) Awards as Pharmaceutical Company of the Year at 2013 American Business Awardssm
    18 hours ago by Business Wire
    Companies Mentioned: ARBU, ARIA

    ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it was honored with two Gold Stevie(R) Awards in the categories of Company of the Year, Pharmaceuticals and Executive of the Year, Pharmaceuticals. Harv...

    Jun 13, 2013

    ARIAD Announces Webcast of Its Annual Shareholders Meeting
    7:35AM ET on Thursday Jun 13, 2013 by Business Wire
    Companies Mentioned: ARIA

    ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that its Annual Meeting of Stockholders will be webcast live on June 20, 2013 and can be accessed by visiting the investor relations section of the Company's ...

    Jun 11, 2013

    Ash Stevens to Manufacture Ponatinib API
    10:30AM ET on Tuesday Jun 11, 2013 by Marketwire
    Companies Mentioned: ARIA

    Ash Stevens, Inc. (ASI), a leading provider of global contract pharmaceutical drug substance development and API (Active Pharmaceutical Ingredient) manufacturing services, announces the U.S. Food and Drug Administration (FDA) has approved ASI's...

    ARIAD Pharmaceuticals Initiates Phase 2 Trial Of Iclusig
    7:45AM ET on Tuesday Jun 11, 2013 by Midnight Trader
    Companies Mentioned: ARIA
    07:45 AM EDT, 06/11/2013 (MidnightTrader) -- ARIAD Pharmaceuticals Inc (ARIA) announced the initiation of the Phase 2 trial of Iclusig (ponatinib) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST). The t...
    ARIAD Announces Initiation of Phase 2 Trial of Ponatinib in Patients with Gastrointestinal Stromal Tumors
    7:35AM ET on Tuesday Jun 11, 2013 by Business Wire
    Companies Mentioned: ARIA

    ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the initiation of the Phase 2 trial of Iclusig(R) (ponatinib) in adult patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST). T...

    Jun 4, 2013

    ARIAD to Present at Upcoming Investor Conferences
    7:30AM ET on Tuesday Jun 04, 2013 by Business Wire
    Companies Mentioned: ARIA

    ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will provide an overview of the Company's business at two upcoming investor conferences being held next week:

    -- The William Blair Growth Sto...

    Jun 2, 2013

    ARIAD Announces Long-Term Durability-of-Response Data on Ponatinib from Ongoing Phase 1 Study
    9:00AM ET on Sunday Jun 02, 2013 by Business Wire
    Companies Mentioned: ARIA

    --72 percent of patients maintain major cytogenetic response; median duration not yet reached

    ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced long-term durability-of-response data from its Phase 1 trial of Iclusi...

    ARIAD Presents Updated Phase 1 Data on AP26113 in Patients with Non-Small Cell Lung Cancer
    9:00AM ET on Sunday Jun 02, 2013 by Business Wire
    Companies Mentioned: ARIA

    --~Investor Meeting and Webcast on Monday, June 3 at 7:30 a.m. CT

    ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated clinical results on its investigational tyrosine kinase inhibitor (TKI), AP26113, i...

    Jun 1, 2013

    ARIAD Presents Analysis of Cardiovascular Risk Profile of Patients from Pivotal PACE Trial of Iclusig(R) (Ponatinib)
    9:00AM ET on Saturday Jun 01, 2013 by Business Wire
    Companies Mentioned: ARIA

    ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced results of evaluation of the cardiovascular risk profile of Philadelphia-positive (Ph+) leukemia patients treated with Iclusig(R) (ponatinib) in the pivotal ...

    ← Newer12Older →

    K=Thousands, M=Millions, B=Billions, TTM=Trailing 12 Month, MRQ=Most Recent Quarter, FYR=Fiscal Year End, NM=Not Meaningful, NA=Not Available

    GAAP = Generally Accepted Accounting Principles used in Financial Statements issued by the company, Non-GAAP = Adjusted Operating Earnings or Revenue used in comparison to Analyst Estimates. Adjustments are typically one-time gains or losses

    8:31 AM June 19, 2013
    Copyright ©2013 TD Waterhouse Canada Inc. All rights reserved.
    Privacy Policy | Internet Security | Legal
    Quotes, News, and Fundamentals provided by
    View restrictions
    News provided by